Ginsenoside C-K
CAS No. 39262-14-1
Ginsenoside C-K ( Ginsenoside K; Ginsenoside compound K )
Catalog No. M18517 CAS No. 39262-14-1
Ginsenoside C-K is a bacterial metabolite of G-Rb1 exhibiting anti-inflammatory effects by reducing iNOS and COX-2.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 91 | In Stock |
|
10MG | 149 | In Stock |
|
25MG | 269 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGinsenoside C-K
-
NoteResearch use only, not for human use.
-
Brief DescriptionGinsenoside C-K is a bacterial metabolite of G-Rb1 exhibiting anti-inflammatory effects by reducing iNOS and COX-2.
-
DescriptionGinsenoside C-K is a bacterial metabolite of G-Rb1 exhibiting anti-inflammatory effects by reducing iNOS and COX-2.
-
SynonymsGinsenoside K; Ginsenoside compound K
-
PathwayOthers
-
TargetOther Targets
-
Recptorcell cycle arrest
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number39262-14-1
-
Formula Weight622.88
-
Molecular FormulaC36H62O8
-
Purity98%
-
SolubilityDMSO : ≥ 100 mg/mL; 160.55 mM
-
SMILESCC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]1[C@]2(CC[C@@H]2[C@@]1(CC[C@@H](C2(C)C)O)C)C)O)C)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yang XD,et al. A review of biotransformation and pharmacology of ginsenoside compound K. Fitoterapia. 2015 Jan;100:208-20.
molnova catalog
related products
-
Cleroindicin F
Cleroindicin F shows cytotoxic activity against some human cancer cells.
-
3-Phenylpropyl isoth...
3-Phenylpropyl isothiocyanate has a stronger inhibitory effect on N-nitrosomethyl-benzylamine (NMBA) tumorigenesis. 3-Phenylpropyl isothiocyanate has chemopreventive effects.
-
Salvianan
Salviane exhibits the most potent cytotoxicity with a CD50 range of 30.4-39.5 microM against HeLa (cervical epitheloid carcinoma), HepG2 (hepatocellular carcinoma), and OVCAR-3 (ovarian adenocarcinoma) cell lines in a dose-dependent manner.